Across TCGA pan-cancer cohorts, SPATA31A1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA31A1 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SPATA31A1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SPATA31A1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, COAD, and LGG are the cancer types where SPATA31A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.956	0.826	.017	18	view →
COAD	OS	Median	III,IV	0.056	0.793	<.001	18	view →
LGG	OS	Median	All	0.183	0.801	<.001	7	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SPATA31A1 tumor-vs-normal RNA expression · all SPATA31A1 data types